In a double-blind, placebo-controlled study involving HD patients, EX527 was well-tolerated with no reported adverse effects; however, it did not alter circulating levels of soluble huntingtin over the short treatment period [230,231]. The gene discussed is HTT; the disease is Huntington disease.